Roche touts study data as eye disease market primed for shake-up

FILE PHOTO: The logo of Swiss pharmaceutical company Roche is seen outside their headquarters in Basel January 30, 2014. REUTERS/Ruben Sprich/File Photo - Copyright Ruben Sprich(Reuters)

By Reuters

Published on 29/10/2018 - 08:04•Updated 19/04/2024 - 10:35

Comments

ZURICH (Reuters) - Swiss drugmaker Roche <ROG.S> on Monday touted data for a new drug against a blindness-causing eye disease that hits millions of older people, the latest sign this multi-billion-dollar market is primed for disruption.

Roche's experimental faricimab, a bispecific antibody, showed potential for extended durability in use against the disease neovascular age-related macular degeneration, it said in a statement.